6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Company News

Panel narrowly backs mipomersen

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 that efficacy and safety data for Kynamro mipomersen from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) support approval to treat patients with...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >